PRL and cancer: We also showed a significant enrichment of metabolic, hormonal and immunological pathways that might enhance the microenvironment of the HCSC dependent on MYC and/or STAT3 such as, Proteoglycans in cancer, Prolactin signaling pathway, Thyroid hormone signaling pathway, Central carbon metabolism in cancer, Inflammatory bowel disease (IBD) and Chemokine signaling pathway (Supplementary Table S2).